Dr. Kurtis Anderson provides patent counseling and intellectual property diligence for biotechnology and pharmaceutical products, including biologics, cellular immunotherapies, and clinical antibody conjugates.
Kurtis advises start-ups and pharmaceutical companies on U.S. and global patent prosecution strategies, including provisional patent drafting and life cycle management. He also provides freedom-to-operate and invalidity analyses in licensing and acquisition evaluations.
Kurtis's doctorate studies focused on structural biology, anti-viral therapeutic design, and molecular biophysics. His research was funded by a Keck Fellowship in Computational and Structural Biology in Biodefense, for the select agent program virus study. Kurtis also synthesized chemically modified and thioated oligonucleotide aptamers, and his scientific work was published in peer-reviewed journals such as the Journal of the American Chemistry Society. Prior to joining Jones Day in 2021, Kurtis was a scientific advisor and a patent agent in pharmaceutical intellectual property for six years in New York City.
- Institute of Molecular Medicine (Post-Doctoral Research Fellow 2015); The University of Texas Medical Branch (Ph.D. in Biochemistry and Molecular Biology 2014); University of Rhode Island (B.S. in Microbiology 2007)
- Registered to practice before the U.S. Patent and Trademark Office. Not licensed to practice by the State Bar of New York.